Nasally Delivered Dry Powder Dosage Forms: Particle Size Analysis
Introduction to Nasal Delivery The delivery of APIs via nasal inhalation is of growing interest to companies looking to exploit the benefits of this delivery route. Delivery targets are typically broken down into three categories Local delivery to the nasal membranes (e.g. for vaccines, antivirals, prophylactics) Systemic delivery by absorption into the bloodstream (e.g. for […]
What’s New In 2023: Exciting Plans For Upperton Pharma Solutions
January 31st 2023 : Newsletter The New Year is always a time for looking ahead and 2023 will no doubt turn out to be a pivotal year in the Upperton Pharma Solutions growth story. In this Newsletter we will be previewing some of the exciting new plans that we have in store for ourselves and […]
Upperton’s new Nottingham facility
18th January 2023 Upperton Pharma Solutions, a leading UK contract development and manufacturing organisation (CDMO), is delighted to announce that it has begun construction work for its new Development and GMP Manufacturing headquarters in Nottingham, UK. Working in close collaboration with its principal Design and Build contractor, T-SQUARED the team officially broke ground on the […]
Build of New Development and Manufacturing Facility
29th November 2022 – Press Release & Newsletter Upperton Pharma Solutions Appoints T-SQUARED for Design and Build of New Development and Manufacturing Facility Upperton Pharma Solutions, a leading UK contract development and manufacturing organisation (CDMO), is delighted to announce that it has appointed T-SQUARED, UK based company, as the principal Design and Build contractor for […]
Upperton Launches ASAPprime® Shelf-Life Stability Testing
November 16th 2022 : Newsletter Upperton has made a significant investment in ASAPprime® software and hardware to enable the company to offer its clients state of the art stability testing. This exciting new platform can be used to generate robust, accelerated chemical stability data and is now being applied at all stages of the product […]
In Vitro Testing of Dry Powder Nasal Delivery Devices
Successful nasal drug delivery of dry powder formulations requires a delivered dose that can penetrate beyond the nasal entrance region and deposit in the peripheral nasal cavity, whilst avoiding deeper penetration to the airways of the lungs. This delivery, or deposition pattern, is determined by the aerodynamic particle size of the powder exiting the device, […]
Characterising the Physical Properties of Spray Dried Powders
The Benefits of Powder Characterisation When developing products containing spray dried powders it is vital that the physical properties of the powders produced are determined. The physical properties of spray dried powders provides important information that can assist during the pre-formulation screening and early process development phases since these properties will have a direct impact […]
Inflexion announces investment into Upperton
21st April 2022 – Press Release Inflexion is pleased to announce it has made a substantial investment into Upperton Pharma Solutions (“Upperton”), a UK-based specialist contract development and manufacturing organisation (“CDMO”) which has expertise in particle engineering for the pharmaceutical industry. Inflexion has invested alongside the founder and the management team who will continue to […]
Upperton Pharma Solutions launches nasal delivery development platform
5th April 2022 – Press Release Nottingham-based contract development and manufacturing organisation (CDMO), Upperton Pharma Solutions, has launched a unique nasal delivery development platform, UpperNose™, to make it easier and faster for small and mid-sized innovators to access the knowledge and capabilities necessary for the successful development of nasal dosage formulations. Drug developers seeking to […]
Growing Interest in Nasal Drug Delivery
Nasal drug delivery route for small molecules and biologics. Recent trends have seen growing interest in exploiting nasal drug delivery as a means of delivering a wide range of drugs including small molecules and larger biologics for a wide range of indications. The nasal cavity is already a well-established delivery route capable of achieving rapid […]